Wedbush Rates TScan Therapeutics (TCRX) buy, $5 Price Target

Wedbush reaffirms TCRX with a $5 price target as shares trade around $0.86, a 467.54% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 9:01 AM EDT · Updated Jun 25, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wedbush rated TScan Therapeutics, Inc. ($TCRX) "buy" with a $5 price target on June 23, 2026.

Since the rating, $TCRX is up 6.5% after 1 week, down 7.6% after 1 month and down 75.0% to date (from the $0.92 close on Jun 23, 2026).

TCRX TScan Therapeutics, Inc.

$0.23 -77.45% year to date

Daily close · Oct 16, 2026

Key Points

On June 23, 2026, Wedbush reiterated its buy rating on TCRX, setting a price target of $5.
Wedbush's $5 price target implies 467.54% upside from TScan Therapeutics, Inc.'s ($TCRX) current $0.88 share price.
Shares of TCRX traded near $0.86 on Tuesday, reflecting ongoing interest from analysts and investors.
Recent insider buying activity and institutional moves highlight continued interest in TCRX.

Get $TCRX trade alerts by text

We text you when insiders, Congress or big funds trade $TCRX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated TScan Therapeutics, Inc. alert may contain errors. Disclosures

On June 23, 2026, Wedbush reiterated its buy rating on TCRX, maintaining a price target of $5. Analyst David Nierengarten reaffirmed the outlook as shares traded around $0.86 on Tuesday.

Analyst rating track record

Wedbush vs. the S&P 500

YTD return +2.87% hypothetical

All-time return +5.33% S&P 500 +42.89%

vs. S&P 500 -37.56% behind the index

Hypothetical returns from Wedbush's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in TCRX

Several institutional investors have recently updated their positions in TCRX. LYNX1 Capital Management LP held steady with 8,019,148 shares valued at about $8.1 million. BVF Inc/IL increased its stake by 338,216 shares, now holding 5,564,290 shares worth approximately $5.6 million, a 6.5% increase. Vanguard Capital Management LLC opened a new position with 2,154,256 shares valued at $2.2 million. Meanwhile, BlackRock, Inc. slightly reduced its holdings by 7,743 shares, now owning 1,840,952 shares valued at $1.9 million, a 0.4% decrease.

TScan Therapeutics, Inc. Stock Up 182.5%

Shares of TCRX traded near $0.86 on Tuesday. The stock's recent movements reflect a continued interest from both investors and analysts, with institutional activities and insider transactions indicating varied strategies around the stock.

12-month forecast

$TCRX price target

TScan Therapeutics, Inc. daily closes and this analyst's $5 target. Not advice.

Insider Buying and Selling at TScan Therapeutics, Inc.

Insider buying activity was notable on May 20, 2026. Several insiders, including Barbara Klencke, Gabriela Gruia, Keith Woods, Katina Dorton, and Garry Nicholson, each purchased 67,000 shares. These transactions were not part of any pre-planned 10b5-1 plans, suggesting a direct vote of confidence in the company's future.

Analysts Set New Price Targets

On June 23, 2026, Wedbush reiterated its buy rating on TCRX with a $5 price target. Needham also reiterated its buy rating, setting a price target of $6 on the same day. The consensus among analysts is a buy rating, with a mean price target reflecting optimism about the stock's potential.

Bottom Line

TCRX has caught the attention of analysts and investors alike, with Wedbush's reaffirmed buy rating and $5 price target underscoring positive sentiment. The stock's price near $0.86 indicates ongoing interest, despite fluctuations. Insider purchases and institutional adjustments suggest strategic positioning as market participants await further developments. Keep in mind, these analyst ratings and institutional filings are backward-looking and reflect past decisions.